Ivan Kadurin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ivan Kadurin has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Annette C. Dolphin
University College London
15 shared publications Annette Dolphin
Department of Neuroscience, Physiology and Pharmacology, University College London, UK
12 shared publicationsManuela Nieto-Rostro
Department of Neuroscience, Physiology and Pharmacology, University College London, Gower Street, London, WC1E 6BT, UK
6 shared publicationsLaurent Ferron
Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK
5 shared publicationsLeon Douglas
University of Southampton, Southampton, United Kingdom
5 shared publicationsWendy S. Pratt
Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK
5 shared publications
Latest Publications
- Open Access
Identification that ADAM17 mediates proteolytic maturation of calcium channel auxiliary α 2 δ subunits, and enables calcium current enhancement
The auxiliary α 2 δ subunits of voltage-gated calcium (Ca V ) channels are key to augmenting expression and function of Ca V 1 and Ca V 2 channels, and are also important drug targets in several therapeutic areas, including neuropathic pain. The α 2 δ proteins are translated as pre-proteins encoding both α 2 and δ, and post-translationally proteolysed into α 2 and δ subunits, which remain associated as a complex. In this study we have identified ADAM17 as a key protease involved in proteolytic processing of pro-α 2 δ-1 and α 2 δ-3 subunits. We provide three lines of evidence: firstly, proteolytic cleavage is inhibited by chemical inhibitors of particular metalloproteases, including ADAM17. Secondly, proteolytic cleavage of both α 2 δ-1 and α 2 δ-3 is markedly reduced in cell lines by knockout of ADAM17 but not ADAM10 . Thirdly, proteolytic cleavage is reduced by the N-terminal active domain of TIMP-3 (N-TIMP-3), which selectively inhibits ADAM17. We have found previously that proteolytic cleavage into mature α 2 δ is essential for the enhancement of Ca V function, and in agreement, knockout of ADAM17 inhibited the ability of α 2 δ-1 to enhance both Ca V 2.2 and Ca V 1.2 calcium currents. Thus, our study identifies ADAM17 as a key protease required for proteolytic maturation of α 2 δ-1 and α 2 δ-3, and thus a potential drug target in neuropathic pain.
Open AccessIdentification that ADAM17 mediates proteolytic maturation of calcium channel auxiliary α 2 δ subunits, and enables calcium current enhancement
The auxiliary α 2 δ subunits of voltage-gated calcium (Ca V ) channels are key to augmenting expression and function of Ca V 1 and Ca V 2 channels, and are also important drug targets in several therapeutic areas, including neuropathic pain. The α 2 δ proteins are translated as pre-proteins encoding both α 2 and δ, and post-translationally proteolysed into α 2 and δ subunits, which remain associated as a complex. In this study we have identified ADAM17 as a key protease involved in proteolytic processing of pro-α 2 δ-1 and α 2 δ-3 subunits. We provide three lines of evidence: firstly, proteolytic cleavage is inhibited by chemical inhibitors of particular metalloproteases, including ADAM17. Secondly, proteolytic cleavage of both α 2 δ-1 and α 2 δ-3 is markedly reduced in cell lines by knockout of ADAM17 but not ADAM10 . Thirdly, proteolytic cleavage is reduced by the N-terminal active domain of TIMP-3 (N-TIMP-3), which selectively inhibits ADAM17. We have found previously that proteolytic cleavage into mature α 2 δ is essential for the enhancement of Ca V function, and in agreement, knockout of ADAM17 inhibited the ability of α 2 δ-1 to enhance both Ca V 2.2 and Ca V 1.2 calcium currents. Thus, our study identifies ADAM17 as a key protease required for proteolytic maturation of α 2 δ-1 and α 2 δ-3, and thus a potential drug target in neuropathic pain.
- 4 November 2020
- Published by H1 Connect
Faculty Opinions recommendation of AKAP5 complex facilitates purinergic modulation of vascular L-type Ca2+ channel CaV1.2.
Elevated blood glucose (hyperglycemia) is one of the hallmark metabolic abnormalities in diabetes, which contributes to the pathogenesis of cardiovascular complications. Hyperglycemia is associated with protein kinase A (PKA)-mediated stimulation of L-type calcium (Cav1.2) channels in arterial vascular smooth muscle cells (SMCs), resulting in increased vasoconstriction. In several subsequent studies (published between 2017 and 2020) the teams of Manuel Navedo and Madeline Nieves-Cintrón illuminated the individual signalling components of the cascade underlying the effects of hyperglycemia in SMCs. Previously, they demonstrated the central role of purinergic Gs-protein coupled PY11 {1} for the stimulation of adenylate cyclase 5 (AC5) {2}, leading to PKA-mediated phosphorylation of Ser1928 of Cav1.2 channels, which results in their stimulation, and consequent vasoconstriction {3}. In the present paper, they identify AKAP5 as the key scaffold molecule that anchors the components of the functional complex (comprising PY11 AC5, PKA and Cav1.2) and facilitates the cascade leading to vasoconstriction in response to hyperglycemia {4}. This study elegantly combines a set of molecular tools and methods to stimulate or block different components of the cascade in mouse and human arterial SMCs or tissue. The approaches used include the broad AC activator forskolin in combination with high glucose, NF546 – an agonist of PY11, or ht-31: a blocker of the PKA-AKAP interaction, in combination with experiments in AKAP5 -/-, and AC5 -/- SMCs. These thorough experiments reveal the specific role of each component of the SMC signalling triggered by hyperglycemia, highlighting the key anchoring role of AKAP5.
- 4 November 2020
- Published by H1 Connect
Faculty Opinions recommendation of AKAP5 complex facilitates purinergic modulation of vascular L-type Ca2+ channel CaV1.2.
Elevated blood glucose (hyperglycemia) is one of the hallmark metabolic abnormalities in diabetes, which contributes to the pathogenesis of cardiovascular complications. Hyperglycemia is associated with protein kinase A (PKA)-mediated stimulation of L-type calcium (Cav1.2) channels in arterial vascular smooth muscle cells (SMCs), resulting in increased vasoconstriction. In several subsequent studies (published between 2017 and 2020) the teams of Manuel Navedo and Madeline Nieves-Cintrón illuminated the individual signalling components of the cascade underlying the effects of hyperglycemia in SMCs. Previously, they demonstrated the central role of purinergic Gs-protein coupled PY11 {1} for the stimulation of adenylate cyclase 5 (AC5) {2}, leading to PKA-mediated phosphorylation of Ser1928 of Cav1.2 channels, which results in their stimulation, and consequent vasoconstriction {3}. In the present paper, they identify AKAP5 as the key scaffold molecule that anchors the components of the functional complex (comprising PY11 AC5, PKA and Cav1.2) and facilitates the cascade leading to vasoconstriction in response to hyperglycemia {4}. This study elegantly combines a set of molecular tools and methods to stimulate or block different components of the cascade in mouse and human arterial SMCs or tissue. The approaches used include the broad AC activator forskolin in combination with high glucose, NF546 – an agonist of PY11, or ht-31: a blocker of the PKA-AKAP interaction, in combination with experiments in AKAP5 -/-, and AC5 -/- SMCs. These thorough experiments reveal the specific role of each component of the SMC signalling triggered by hyperglycemia, highlighting the key anchoring role of AKAP5.
- 1 May 2020
- Published by Elsevier in Cell Calcium
- Vol. 87, 102180
Fight or flight: The culprit is lurking in the neighbourhood
- 1 May 2020
- Published by Elsevier in Cell Calcium
- Vol. 87, 102180
Fight or flight: The culprit is lurking in the neighbourhood
- 13 December 2019
- Published by H1 Connect
- Vol. 8
Faculty Opinions recommendation of Novel charged sodium and calcium channel inhibitor active against neurogenic inflammation.
Voltage-dependent sodium and calcium channels in pain-initiating nociceptor neurons are attractive targets for new analgesics. We made a permanently charged cationic derivative of an N-type calcium channel-inhibitor. Unlike cationic derivatives of local anesthetic sodium channel blockers like QX-314, this cationic compound inhibited N-type calcium channels more effectively with extracellular than intracellular application. Surprisingly, the compound is also a highly effective sodium channel inhibitor when applied extracellularly, producing more potent inhibition than lidocaine or bupivacaine. The charged inhibitor produced potent and long-lasting analgesia in mouse models of incisional wound and inflammatory pain, inhibited release of the neuropeptide calcitonin gene-related peptide (CGRP) from dorsal root ganglion neurons, and reduced inflammation in a mouse model of allergic asthma, which has a strong neurogenic component. The results show that some cationic molecules applied extracellularly can powerfully inhibit both sodium channels and calcium channels, thereby blocking both nociceptor excitability and pro-inflammatory peptide release. © 2019, Lee et al.
- 13 December 2019
- Published by H1 Connect
- Vol. 8
Faculty Opinions recommendation of Novel charged sodium and calcium channel inhibitor active against neurogenic inflammation.
Voltage-dependent sodium and calcium channels in pain-initiating nociceptor neurons are attractive targets for new analgesics. We made a permanently charged cationic derivative of an N-type calcium channel-inhibitor. Unlike cationic derivatives of local anesthetic sodium channel blockers like QX-314, this cationic compound inhibited N-type calcium channels more effectively with extracellular than intracellular application. Surprisingly, the compound is also a highly effective sodium channel inhibitor when applied extracellularly, producing more potent inhibition than lidocaine or bupivacaine. The charged inhibitor produced potent and long-lasting analgesia in mouse models of incisional wound and inflammatory pain, inhibited release of the neuropeptide calcitonin gene-related peptide (CGRP) from dorsal root ganglion neurons, and reduced inflammation in a mouse model of allergic asthma, which has a strong neurogenic component. The results show that some cationic molecules applied extracellularly can powerfully inhibit both sodium channels and calcium channels, thereby blocking both nociceptor excitability and pro-inflammatory peptide release. © 2019, Lee et al.
- 3 December 2019
- Published by H1 Connect
Faculty Opinions recommendation of Cryo-EM structures of apo and antagonist-bound human Cav3.1.
We previously learned a lot about high-voltage activated (HVA) calcium channels from the cryo-EM structures of Cav1.1 in complex with auxiliary protein subunits {1,2}, and with archetypal antagonistic drugs, nifedipine, diltiazem, and verapamil {3}. Now, the same laboratory of Professor Nieng Yan has published their newest cryo-EM structure, widely anticipated in the field: that of a member of the low-voltage activated (LVA) channels, Cav3.1. Not only that: the cryo-EM structure of human Cav3.1 is reported both alone and in complex with a highly Cav3-selective blocker, Z944. With both Cav1 and CaV3 channel structures now available, these studies are now providing powerful structural tools for researchers in the field, allowing comparison of functional differences between the different Cav subfamilies. For example, unlike Cav1 and Cav2, Cav3 channels do not require auxiliary α2δ and β protein subunits to be fully functional. The structural incompatibility between α2δ and Cav3.1 is now made evident as one of the extracellular helix loops of Cav3.1 is rigidified through disulfide bond formation, causing a structural clash with the potential position of the Cache domain of α2δ. Together, these CaV structures help our understanding of channel function, and the effect of genetic mutations as well as aiding future drug design.
- 3 December 2019
- Published by H1 Connect
Faculty Opinions recommendation of Cryo-EM structures of apo and antagonist-bound human Cav3.1.
We previously learned a lot about high-voltage activated (HVA) calcium channels from the cryo-EM structures of Cav1.1 in complex with auxiliary protein subunits {1,2}, and with archetypal antagonistic drugs, nifedipine, diltiazem, and verapamil {3}. Now, the same laboratory of Professor Nieng Yan has published their newest cryo-EM structure, widely anticipated in the field: that of a member of the low-voltage activated (LVA) channels, Cav3.1. Not only that: the cryo-EM structure of human Cav3.1 is reported both alone and in complex with a highly Cav3-selective blocker, Z944. With both Cav1 and CaV3 channel structures now available, these studies are now providing powerful structural tools for researchers in the field, allowing comparison of functional differences between the different Cav subfamilies. For example, unlike Cav1 and Cav2, Cav3 channels do not require auxiliary α2δ and β protein subunits to be fully functional. The structural incompatibility between α2δ and Cav3.1 is now made evident as one of the extracellular helix loops of Cav3.1 is rigidified through disulfide bond formation, causing a structural clash with the potential position of the Cache domain of α2δ. Together, these CaV structures help our understanding of channel function, and the effect of genetic mutations as well as aiding future drug design.
- 13 November 2019
- Published by H1 Connect
Faculty Opinions recommendation of Direct, gabapentin-insensitive interaction of a soluble form of the calcium channel subunit α2δ-1 with thrombospondin-4.
This paper by El-Awaad et al. demonstrates, by using purified proteins in an ELISA-based assay, a direct interaction between thrombospondin-4 (but not other thrombospondins) and soluble truncations of α2δ-1. Of great interest, the molecular interaction between α2δ-1 and thrombospondin-4 demonstrated here was unaffected by gabapentin (a drug that binds to α2δ-1, which is used in the treatment of neuropathic pain). Several previous studies, detailed in the paper, describe interactions of thrombospondins-1 and -2 (as well as thrombospondin-4) with α2δ-1, and show that gabapentin inhibits both these interactions and the effects of thrombospondins on synaptogenesis. The biochemical evidence presented here does not confirm direct interactions between α2δ-1 and thrombospondins-1 and -2 in vitro, neither the inhibitory effect of GBP on the interaction with thrombospondin-4, which raises questions regarding the exact mechanism by which GBP can block the thrombospondin-induced changes. Interestingly, in this paper, when α2δ-1 was expressed on the surface of cells and they were exposed to purified thrombospondin-4, no interaction could be seen. This is in agreement with a previous study in which thrombospondin-4 was either co-expressed with α2δ-1 or secreted from neighbouring cells {1}. This suggests that under these physiological conditions, there is no interaction of sufficient affinity to be demonstrated by these techniques. This study shows that it is important to use purified proteins to demonstrate and quantify the affinity of direct interactions, and that, although co-immunoprecipitation can give an indication of interactions, these might be indirect via an intermediary protein.
- 13 November 2019
- Published by H1 Connect
Faculty Opinions recommendation of Direct, gabapentin-insensitive interaction of a soluble form of the calcium channel subunit α2δ-1 with thrombospondin-4.
This paper by El-Awaad et al. demonstrates, by using purified proteins in an ELISA-based assay, a direct interaction between thrombospondin-4 (but not other thrombospondins) and soluble truncations of α2δ-1. Of great interest, the molecular interaction between α2δ-1 and thrombospondin-4 demonstrated here was unaffected by gabapentin (a drug that binds to α2δ-1, which is used in the treatment of neuropathic pain). Several previous studies, detailed in the paper, describe interactions of thrombospondins-1 and -2 (as well as thrombospondin-4) with α2δ-1, and show that gabapentin inhibits both these interactions and the effects of thrombospondins on synaptogenesis. The biochemical evidence presented here does not confirm direct interactions between α2δ-1 and thrombospondins-1 and -2 in vitro, neither the inhibitory effect of GBP on the interaction with thrombospondin-4, which raises questions regarding the exact mechanism by which GBP can block the thrombospondin-induced changes. Interestingly, in this paper, when α2δ-1 was expressed on the surface of cells and they were exposed to purified thrombospondin-4, no interaction could be seen. This is in agreement with a previous study in which thrombospondin-4 was either co-expressed with α2δ-1 or secreted from neighbouring cells {1}. This suggests that under these physiological conditions, there is no interaction of sufficient affinity to be demonstrated by these techniques. This study shows that it is important to use purified proteins to demonstrate and quantify the affinity of direct interactions, and that, although co-immunoprecipitation can give an indication of interactions, these might be indirect via an intermediary protein.
- Open Access
- 1 October 2019
- Published by Elsevier in Cell Reports
- Vol. 29 (1) , 22-33.e5
Disruption of the Key Ca2+ Binding Site in the Selectivity Filter of Neuronal Voltage-Gated Calcium Channels Inhibits Channel Trafficking
- 1 October 2019
- Published by Elsevier in Cell Reports
- Vol. 29 (1) , 22-33.e5
Open AccessDisruption of the Key Ca2+ Binding Site in the Selectivity Filter of Neuronal Voltage-Gated Calcium Channels Inhibits Channel Trafficking
- 13 September 2019
- Published by H1 Connect
Faculty Opinions recommendation of A potent voltage-gated calcium channel inhibitor engineered from a nanobody targeted to auxiliary CaVβ subunits.
In this study, Morgenstern et al. engineered a remarkably potent, genetically-encoded inhibitor (named Cav-aβlator) of high-voltage-activated calcium channels (HVACCs). Cav-aβlator strongly inhibited whole-cell currents of different subtypes of HVACCs. The authors engineered Cav-aβlator as a fusion protein of a specific nanobody (nb-F3) against the auxiliary β subunits of the HVACC complex with the catalytic domain of domain of an E3 ubiquitin ligase Nedd4L (nb-F3-Nedd4L). They demonstrated that the nb-F3 alone effectively binds all tested β subunits without affecting their expression and their function within HVACC complexes. In contrast, the fusion protein nb-F3-Nedd4L (Cav-aβlator) strongly inhibited the whole-cell currents of HVACCs expressed in heterologous cells, as well as the endogenous HVACCs in their native environment (DRG neurons, cardiomyocytes, and pancreatic β cells). Immunocytochemical and biochemical experiments provide additional evidence that the mechanism of action of Cav-aβlator is via translocating the ubiquitinated HVACCs from their functional domains in the plasma membrane into Rab7-positive endosomes. This work uncovers a highly effective strategy for functional targeting of HVACCs via their β subunits (Cav-aβlator), as opposed to previous approaches based on inhibition of the association between the auxiliary β with HVACCs. Potentially, although its action is intracellular, Cav-aβlator could also be employed for development of novel therapeutic strategies for treatment of cardiovascular and neuronal diseases caused by HVACCs dysfunctions such as cardiac arrhythmia, hypertension, or neuropathic pain.
- 13 September 2019
- Published by H1 Connect
Faculty Opinions recommendation of A potent voltage-gated calcium channel inhibitor engineered from a nanobody targeted to auxiliary CaVβ subunits.
In this study, Morgenstern et al. engineered a remarkably potent, genetically-encoded inhibitor (named Cav-aβlator) of high-voltage-activated calcium channels (HVACCs). Cav-aβlator strongly inhibited whole-cell currents of different subtypes of HVACCs. The authors engineered Cav-aβlator as a fusion protein of a specific nanobody (nb-F3) against the auxiliary β subunits of the HVACC complex with the catalytic domain of domain of an E3 ubiquitin ligase Nedd4L (nb-F3-Nedd4L). They demonstrated that the nb-F3 alone effectively binds all tested β subunits without affecting their expression and their function within HVACC complexes. In contrast, the fusion protein nb-F3-Nedd4L (Cav-aβlator) strongly inhibited the whole-cell currents of HVACCs expressed in heterologous cells, as well as the endogenous HVACCs in their native environment (DRG neurons, cardiomyocytes, and pancreatic β cells). Immunocytochemical and biochemical experiments provide additional evidence that the mechanism of action of Cav-aβlator is via translocating the ubiquitinated HVACCs from their functional domains in the plasma membrane into Rab7-positive endosomes. This work uncovers a highly effective strategy for functional targeting of HVACCs via their β subunits (Cav-aβlator), as opposed to previous approaches based on inhibition of the association between the auxiliary β with HVACCs. Potentially, although its action is intracellular, Cav-aβlator could also be employed for development of novel therapeutic strategies for treatment of cardiovascular and neuronal diseases caused by HVACCs dysfunctions such as cardiac arrhythmia, hypertension, or neuropathic pain.
- 5 July 2019
- Published by H1 Connect
Faculty Opinions recommendation of Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy.
In this is exciting new study, Khanna et al. performed structure-based virtual screening of 50,000 small molecules that potentially target the interaction interface between voltage-gated Calcium (Cav) channel Cavα1 subunits with Cavβ subunits. They identified a compound (IPPQ) that preferentially inhibits Cavα1/Cavβ interactions of N-type Cav2.2 channels, for all β subunits except β4. The authors demonstrate that IPPQ causes a decrease of Cav2.2 synaptic localisation, inhibition of Cav2.2 currents in rat dorsal root ganglion (DRG) neurons and decreased spinal excitatory synaptic transmission. Furthermore, IPPQ effectively reversed allodynia and hyperalgesia in animal models in vivo. This study uncovers the potential therapeutic strategy of inhibiting the association between N-type Cav2.2 channels with auxiliary β subunits as a novel avenue for treatment of neuropathic pain.
- 5 July 2019
- Published by H1 Connect
Faculty Opinions recommendation of Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy.
In this is exciting new study, Khanna et al. performed structure-based virtual screening of 50,000 small molecules that potentially target the interaction interface between voltage-gated Calcium (Cav) channel Cavα1 subunits with Cavβ subunits. They identified a compound (IPPQ) that preferentially inhibits Cavα1/Cavβ interactions of N-type Cav2.2 channels, for all β subunits except β4. The authors demonstrate that IPPQ causes a decrease of Cav2.2 synaptic localisation, inhibition of Cav2.2 currents in rat dorsal root ganglion (DRG) neurons and decreased spinal excitatory synaptic transmission. Furthermore, IPPQ effectively reversed allodynia and hyperalgesia in animal models in vivo. This study uncovers the potential therapeutic strategy of inhibiting the association between N-type Cav2.2 channels with auxiliary β subunits as a novel avenue for treatment of neuropathic pain.
- 9 April 2019
- Published by H1 Connect
Faculty Opinions recommendation of Presynaptic α2δ-2 Calcium Channel Subunits Regulate Postsynaptic GABAA Receptor Abundance and Axonal Wiring.
The α2δ subunits are large extracellular glycoproteins traditionally established as auxiliary subunits modulating the functional properties and the trafficking of voltage-gated calcium (Cav) channels. More recently, α2δ proteins have also been emerging as novel regulators of synapse formation {1}, trans-synaptic signalling {2,3}, axonal outgrowth and regeneration {4}. This exciting paper by the group of Gerard Obermair now reveals that the presynaptic overexpression of α2δ-2 (but not any of the other mammalian α2δ isoforms) increases the clustering of postsynaptic components characteristic of inhibitory synapses, such as GABAA receptors and gephyrin proteins. Geisler et al. provide extensive immunocytochemical evidence to demonstrate that the identity of the pre-synaptic neurotransmitter does not affect the ability of α2δ-2 to induce post-synaptic GABAA R/gephyrin clustering. This is demonstrated by the ability of presynaptic α2δ-2 to induce the formation of mismatched synapses with glutamatergic presynaptic boutons and GABAA-R-containing postsynaptic sites. Further experiments support the authors’ hypothesis that the formation of mismatched synapses is associated with an aberrant wiring, and suggest that α2δ-2 isoform can act trans-synaptically. The study unveils a novel role for the neuronal α2δ-2 proteins and opens new routes for future research. For example, it would be interesting to investigate if a direct binding of α2δ-2 across the synaptic cleft with yet unidentified neuronal factor(s) in the post-synaptic neuron (including GABAA-R) determines the described effects.
- 9 April 2019
- Published by H1 Connect
Faculty Opinions recommendation of Presynaptic α2δ-2 Calcium Channel Subunits Regulate Postsynaptic GABAA Receptor Abundance and Axonal Wiring.
The α2δ subunits are large extracellular glycoproteins traditionally established as auxiliary subunits modulating the functional properties and the trafficking of voltage-gated calcium (Cav) channels. More recently, α2δ proteins have also been emerging as novel regulators of synapse formation {1}, trans-synaptic signalling {2,3}, axonal outgrowth and regeneration {4}. This exciting paper by the group of Gerard Obermair now reveals that the presynaptic overexpression of α2δ-2 (but not any of the other mammalian α2δ isoforms) increases the clustering of postsynaptic components characteristic of inhibitory synapses, such as GABAA receptors and gephyrin proteins. Geisler et al. provide extensive immunocytochemical evidence to demonstrate that the identity of the pre-synaptic neurotransmitter does not affect the ability of α2δ-2 to induce post-synaptic GABAA R/gephyrin clustering. This is demonstrated by the ability of presynaptic α2δ-2 to induce the formation of mismatched synapses with glutamatergic presynaptic boutons and GABAA-R-containing postsynaptic sites. Further experiments support the authors’ hypothesis that the formation of mismatched synapses is associated with an aberrant wiring, and suggest that α2δ-2 isoform can act trans-synaptically. The study unveils a novel role for the neuronal α2δ-2 proteins and opens new routes for future research. For example, it would be interesting to investigate if a direct binding of α2δ-2 across the synaptic cleft with yet unidentified neuronal factor(s) in the post-synaptic neuron (including GABAA-R) determines the described effects.